![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjtcOn7Ror_2Ba_OHKj8qNxXvaOFJ8JaFMhzIuEGT5PO9AL4Ezp5207Qn1r63IrTsJ3K_MNmBlvFJ5wTkej1b8tj_xgQwiv06EicLHIULkwfViA3qyOQqe7i5G-fmS_aH8aO9M2z4zW-do/s1600/AGIO+2014-01+daily+finviz.png)
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgs038et36IofhQZLWhOgDTvg-z6iVSkM7FTSQE5iuCbykbn0fjQT8x0I1PtgvjiTxor87LcKDmcab0v31zZa-UUhL-BmpXBYS_qjKNOqQr3CAEZVTWZTDUQNdEAHRPdTMi3ZaYEFDw5OM/s1600/AGIO+2014-01+daily.png)
Address
2nd Floor, 38 Sidney Street
CAMBRIDGE, MA 02139-4169
United States
CAMBRIDGE, MA 02139-4169
United States
Website
www.agios.comKey stats and ratios
Q2 (Jun '13) | 2012 | |
Net profit margin | -137.52% | -80.07% |
Operating margin | -136.02% | -91.59% |
EBITD margin | - | -86.90% |
Return on average assets | -29.16% | -12.13% |
Return on average equity | - | - |
Employees | 85 |
No comments:
Post a Comment